درباره این اپیزود
Cardiovascular disease has long been managed by slowing its relentless progression. But Matthew O'Connor, CEO of Scientific Affairs at Cyclarity Therapeutics, is betting on an outright paradigm shift: treating atherosclerotic plaque with therapies designed to actively reverse disease, not simply manage symptoms or risk.
In this episode, David Brühlmann explores the strategy, regulatory journey, and manufacturing realities behind Cyclarity's unconventional cyclodextrin-based approach—a molecule sitting at the crossroads of small and large molecule drug development.
Topics discussed:
- Insights into the company's clinical development progress, including completion of a first-in-human study and what comes next (02:47)
- How the FDA views drugs that don't fit traditional categories and how this influences development pathways (04:35)
- The challenges and considerations in demonstrating efficacy for drugs designed to reduce heart attacks and strokes (05:22)
- Cost considerations in manufacturing the cyclodextrin dimer and how it compares to biologics and GLP-1 drugs (08:14)
- Vision for how cardiovascular disease may be diagnosed and treated a decade from now, including the role of imaging and prevention (10:24)
- Broader implications for treating age-related diseases by targeting toxic metabolites in the body (14:25)
- Why next-generation therapeutics may be built not by sticking to old modalities but by tackling root causes with custom solutions (16:10)
- Reflections on making new drugs both safe and fundamentally beneficial, minimizing side effects (17:10)
Smart insight: Start with the problem, not the modality. Matthew O'Connor argues that instead of defaulting to an antibody, a small molecule or a gene therapy, developers should build a custom solution to the problem they're trying to solve. A drug that suppresses a pathway across the whole body brings side effects you have to manage. A drug that removes something harmful, like oxidized cholesterol, can have side effects that are actually beneficial. His goal for the next generation of drugs is ones that simply make people healthier.
When a drug is too big to be a small molecule and too small to be a biologic, every CMC decision gets harder. These episodes look at what it takes to develop, characterize and manufacture a modality that doesn't fit an existing box.
- Episodes 281 - 282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar
- Episodes 207 - 208: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo
- Episodes 197 - 198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
Connect with Matthew O'Connor:
Website: www.cyclaritytx.com
LinkedIn: www.linkedin.com/in/droki
Email: matthew.oconnor@cyclaritytx.com
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
